We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Seer, a liquid biopsy company aimed at querying the body’s proteome, has emerged from stealth with $36 million in funding to develop early-warning tests for cancer and neurological diseases.